Results 31 to 40 of about 21,372 (208)

Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma

, 2020
Objectives: Venetoclax, an orally available BCL2‐selective inhibitor, has demonstrated promising single‐agent anti‐tumour activity in myeloma especially patients with t(11;14).
Chim, CS, Wong, KY
core   +1 more source

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies [PDF]

, 2022
The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Since there is no common genetic alteration causing resistance to venetoclax in CLL and B cell lymphoma, we asked if epigenetic events might be involved in ...
Schäfer, S., Yang, T.-P., Abken, H., Wasserburger, E., Kreuzer, K.-A., Herling, C., da Palma Guerreiro , A., Kreuzer, K., Herwig, R., Reinhardt, H. C., Faitschuk-Meyer, E., Claasen, J., Yang, T.P., Nürnberg, P., Eichhorst, B., Herling, C. D., Büttner, R., Schäfer, S. C., Meder, L., Reinhardt, H., Kashkar, H., Eichhorst , B., Pallasch, C., Lorsy, E., Lienhard, M., Peifer, M., Schweiger, M. R., Pallasch, C. P., Hallek, M., Frenzel, L. P., Herling, C.D., Ullrich, R., Schäfer, S.C., Oliverio, M., Feldmann, T., von Jan, J., Pallasch, C.P., da Palma Guerreiro, A., Reinhardt, H.C., Herling, M., Beckmann, L., Schweiger, M.R., Grimm , C., Ullrich, R. T., Frenzel, L., Yang, T., Ullrich, R.T., Grimm, C., Buettner, R., Hartley, J., Thomalla, D., Frenzel, L.P., Kreuzer, K.A., Schweiger, M., Nieper, P., Kisis, I., Altmüller, J., Knittel, G., Merkel, O.   +58 more
core   +1 more source

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

Haematologica, 2022
BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid ...
Yvonne J. Thus, Martin F.M. de Rooij, Nathalie Swier, Roderick L. Beijersbergen, Jeroen E.J. Guikema, Marie-José Kersten, Eric Eldering, Steven T. Pals, Arnon P. Kater, Marcel Spaargaren   +9 more
doaj   +1 more source

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL [PDF]

, 2020
Chronic lymphocytic leukemia (CLL) cells cycle between lymph node (LN) and peripheral blood (PB) and display major shifts in Bcl-2 family members between those compartments.
Bax, Danique J. C., Kater, Arnon P., Eldering, E., Bax, Danique Johanna Cornelia, Bax, D.J.C., Chiodin, Giorgia, Ter Burg, Johanna, Kielbassa, Karoline, Tam, C., Chiodin, G., Kielbassa, K., Fernandes, S.M., Eldering, Eric, Borst, Jannie, Borst, J., Brown, J.R., Kater, A.P., Haselager, M.V., Haselager, Marco Vincent, Dubois, J., Burg, J. ter, Haselager, Marco V., Fernandes, Stacey Marie, Brown, Jennifer R., Tam, Constantine, Fernandes, Stacey M., Dubois, Julie, Forconi, Francesco, Forconi, F.   +28 more
core   +1 more source

Budget impact analysis of acalabrutinib plus venetoclax in chronic lymphocytic leukemia

Фармакоэкономика
Objective: To evaluate the budget impact of a fixed-duration combination (FC) “acalabrutinib + venetoclax” regimen for treatmentnaive adults with chronic lymphocytic leukemia (CLL), unmutated IGHV, and absence of del(17p) or mutations in TP53 in the ...
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Lutova, E. A. Popova   +4 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

Hematology, Transfusion and Cell Therapy
Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive ...
Lauro Fabián Amador-Medina, Erick Crespo-Solís, Francisco Javier Turrubiates-Hernández, Karla Edith Santibañez-Bedolla   +3 more
doaj   +1 more source

Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor

Clinical and Translational Science
Venetoclax, a highly potent BCL‐2 inhibitor, is indicated for treatment of some hematologic malignancies as monotherapy, and/or in combination with other agents.
Ahmed Hamed Salem, Rajeev M. Menon
doaj   +1 more source

Importin 7 mediates the nuclear import of HIV‐1 integrase via a specific interacting interface

FEBS Open Bio, EarlyView.
HIV‐1 integrase enables viral DNA integration into the host genome. By binding to the core domain of the host protein Importin 7 via its C‐terminal domain, the integrase is transported across the nuclear membrane into the nucleus, where integration of the viral genome into host DNA takes place. This translocation is a critical step for subsequent viral
Juana Bana, Avigail Yariv, Tal Oppenheim, Hadar Amartely, Dana Reichmann, Oded Livnah   +5 more
wiley   +1 more source

Dissecting The Mechanisms of Venetoclax Resistance In Myelodysplastic Syndromes [PDF]

, 2021
Myelodysplastic syndromes (MDS) are a class of heterogeneous clonal hematopoietic disorders. The current standard of care for MDS is the hypomethylating agent (HMA)-based therapy.
Chen, Shuaitong
core   +1 more source